Mayne Pharma Group Ltd (ASX:MYX)
A$ 4.78 0.11 (2.36%) Market Cap: 388.36 Mil Enterprise Value: 277.90 Mil PE Ratio: 0 PB Ratio: 0.86 GF Score: 72/100

Half Year 2022 Mayne Pharma Group Ltd Earnings Call Transcript

Feb 24, 2022 / 10:30PM GMT
Release Date Price: A$5 (-7.41%)
Operator

Good day, and welcome to the Mayne Pharma Half Year Results Conference Call. At this time, I would like to turn the conference over to Mr. Scott Richards, the CEO of the company. Please go ahead, sir. Thank you.

Scott Anthony Richards
Mayne Pharma Group Limited - MD, CEO & Executive Director

Thank you, operator, and good morning, everybody. Thank you for joining us today to discuss Mayne Pharma's half year results for 2022. And joining me on the call is Peter Paltoglou, our Chief Financial Officer.

Today, I will provide you with an overview of the results together with the business and strategy update, and Peter will provide further details on the financial results, and then we'll open up the call to questions.

On Slide 5, we outline the key financials. Revenues were $196 million. Reported EBITDA was $49 million, and underlying EBITDA was $24 million.

Removing the impact of our launch investment in NEXTSTELLIS from the results, underlying EBITDA was $44 million, up 11% from the prior corresponding period and up 35% on the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot